Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 11/20 | 0.56 |
| ▸ | NPY1R | P25929 | 6/20 | 0.56 |
| ▸ | NPY2R | P49146 | 4/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.56 |
| ▸ | MME | P08473 | 1/20 | 0.50 |
| ▸ | FNTA | P49354 | 3/20 | 0.49 |
| ▸ | FNTB | P49356 | 3/20 | 0.49 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1737572 | 1.00 | NPY4R (0.56) | NPY4RNPY1RNPY2RNPY5RMME | |
| SCHEMBL31184436 | 1.00 | NPY4R (0.56) | NPY4RNPY1RNPY2RNPY5RMME | |
| SCHEMBL29531710 | 1.00 | NPY4R (0.56) | NPY4RNPY1RNPY2RNPY5RMME | |
| SCHEMBL10940118 | 0.98 | NPY4R (0.60) | NPY4RNPY1RNPY2RNPY5RMME | |
| SCHEMBL29666714 | 0.98 | NPY4R (0.60) | NPY4RNPY1RNPY2RNPY5RMME | |
| SCHEMBL29800135 | 0.97 | NPY4R (0.61) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30046023 | 0.97 | NPY4R (0.61) | NPY4RNPY1RNPY2RNPY5R | |
| Acetic Acid SCHEMBL9191722 | 0.97 | NPY4R (0.56) | NPY4RNPY1RNPY2RNPY5RMME | |
| Acetic Acid SCHEMBL9191707 | 0.97 | NPY4R (0.56) | NPY4RNPY1RNPY2RNPY5RMME | |
| SCHEMBL29666228 | 0.96 | NPY4R (0.56) | NPY4RNPY1RNPY2RNPY5RMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 210 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367115-A1 | Excipients To Reduce the Viscosity of Antibody Formulations and Formulation Compositions | AMGEN INC. (US) | 2025-12-04 | — | — | US | claimed |
| US-12377110-B2 | Fospropofol methods and compositions | EPALEX CORPORATION (US) | 2025-08-05 | — | — | US | claimed |
| US-12257343-B2 | Excipients to reduce the viscosity of antibody formulations and formulation compositions | AMGEN INC. (US) | 2025-03-25 | — | — | US | claimed |
| CN-119119176-A | Camptothecin derivatives | 伊缪诺金公司 | 2024-12-13 | — | — | CN | claimed |
| CN-119080883-A | Antibacterial peptide and application thereof | 合肥科生景肽生物科技有限公司 | 2024-12-06 | — | — | CN | claimed |
| CN-113766954-B | Camptothecin derivatives | 伊缪诺金公司 | 2024-09-24 | — | — | CN | claimed |
| WO-2024132726-A1 | SERUM PEPTIDE PATTERNS FOR DIAGNOSTICS OF ACUTE ISCHEMIC STROKE IN HUMANS AND DIFFERENTIAL DIAGNOSIS OF ACUTE ISCHEMIC STROKE FROM INTRACRANIAL HEMORRHAGIC STROKE | UNIWERSYTET GDANSKI (PL) | 2024-06-27 | — | — | WO | claimed |
| EP-4364754-A2 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2024-05-08 | — | — | EP | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| US-20230094471-A1 | CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES | IMMUNOGEN, INC. (US) | 2023-03-30 | — | — | US | claimed |
| US-20230084521-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2023-03-16 | — | — | US | claimed |
| CN-115047120-A | Dansyl chloride derivatization method for analyzing and detecting dipeptide substances in white spirit Daqu | 贵州茅台酒股份有限公司 | 2022-09-13 | — | — | CN | claimed |
| US-20220133711-A1 | CAMPTOTHECIN DERIVATIVES | IMMUNOGEN, INC. | 2022-05-05 | — | — | US | claimed |
| US-20220105050-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2022-04-07 | — | — | US | claimed |
| EP-3478121-A1 | METHOD FOR SAMPLING GINGIVAL METABOLITES | The Procter and Gamble Company (US) | 2019-05-08 | — | — | EP | claimed |
| CN-109414109-A | Method for sampling gums metabolin | 宝洁公司 | 2019-03-01 | — | — | CN | claimed |
| US-9964472-B2 | Methods for sampling gingival metabolites | THE PROCTER & GAMBLE COMPANY (US) | 2018-05-08 | — | — | US | claimed |
| US-20180003598-A1 | METHODS FOR SAMPLING GINGIVAL METABOLITES | THE PROCTER & GAMBLE COMPANY | 2018-01-04 | — | — | US | claimed |
| WO-2018005335-A1 | METHOD FOR SAMPLING GINGIVAL METABOLITES | THE PROCTER & GAMBLE COMPANY (US) | 2018-01-04 | — | — | WO | claimed |
| US-20260146045-A1 | COMPOSITIONS AND USES THEREOF | SOLVE THERAPEUTICS, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| WO-2026107381-A1 | DNA POLYMERASE THETA INHIBITORS, COMPOSITIONS THEREOF, COMPOSITIONS FURTHER COMPRISING A DNA DEPENDENT PROTEIN KINASE, AND USES OF BOTH IN GENE EDITING FIELD | JUNO THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-3972649-B1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20260102506-A1 | COMPOSITIONS AND USES THEREOF | SOLVE THERAPEUTICS INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12590131-B2 | Antimicrobial peptides with alpha-core helices | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER (US) | 2026-03-31 | — | — | US | disclosed |
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2026-03-05 | — | — | US | disclosed |
| US-20260036547-A1 | METHODS FOR DETECTING METABOLITES USING A MICROFLUIDIC-BASED CE-MS SYSTEM | ASTRAZENECA AB (SE) | 2026-02-05 | — | — | US | disclosed |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2026-01-29 | — | — | US | disclosed |
| EP-4676540-A1 | PANRAS INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | Novartis AG (CH) | 2026-01-14 | — | — | EP | disclosed |
| US-20260000777-A1 | NECTIN-4 ANTIBODY CONJUGATES AND USES THEREOF | ARARIS BIOTECH AG (CH) | 2026-01-01 | — | — | US | disclosed |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-12-25 | — | — | US | disclosed |
| US-20250367115-A1 | Excipients To Reduce the Viscosity of Antibody Formulations and Formulation Compositions | AMGEN INC. (US) | 2025-12-04 | — | — | US | disclosed |
| CN-120988066-A | Antibacterial peptide, application thereof and medicine containing antibacterial peptide | 丽水市中心医院 | 2025-11-21 | — | — | CN | disclosed |
| US-20250340591-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | ANYGEN CO LTD (KR) | 2025-11-06 | — | — | US | disclosed |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-20250326853-A1 | FORMULATIONS OF HUMAN ANTI-RANKL ANTIBODIES, AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4635569-A2 | METHODS OF DELIVERING A NEUROPROTECTIVE POLYPEPTIDE TO THE CENTRAL NERVOUS SYSTEM | Peptron, Inc. (KR) | 2025-10-22 | — | — | EP | disclosed |
| US-20250312361-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | EPALEX CORP (US) | 2025-10-09 | — | — | US | disclosed |
| EP-4604949-A2 | COMPOSITIONS AND USES THEREOF | Solve Therapeutics, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250263491-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-08-21 | — | — | US | disclosed |
| US-12377110-B2 | Fospropofol methods and compositions | EPALEX CORPORATION (US) | 2025-08-05 | — | — | US | disclosed |
| US-12364768-B2 | Nectin-4 antibody conjugates and uses thereof | ARARIS BIOTECH AG (CH) | 2025-07-22 | — | — | US | disclosed |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2025-06-05 | — | — | US | disclosed |
| WO-2025111431-A1 | ANTI-CD7 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | LES LABORATOIRES SERVIER (FR) | 2025-05-30 | — | — | WO | disclosed |
| EP-4558511-A2 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | Firefly Bio, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-4554625-A1 | EPCAM IMMUNOCONJUGATES AND USES THEREOF | CytomX Therapeutics, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| CN-120005928-A | Dynamic regulation and control system, strain, construction method of strain and application of strain in microbial fuel cell | 天津科技大学 | 2025-05-16 | — | — | CN | disclosed |
| US-12269900-B2 | Inhibitors of β integrin-G protein α subunit binding interactions | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-04-08 | — | — | US | disclosed |
| CN-119751555-A | Cicada pupa polypeptide with ACE (angiotensin converting enzyme) inhibitory activity as well as preparation method and application thereof | 江南大学 | 2025-04-04 | — | — | CN | disclosed |
| EP-4525926-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | Novartis AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| EP-4525928-A1 | ANTIBODY DRUG CONJUGATES | Novartis AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| EP-4525927-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | Novartis AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| EP-4525925-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | Novartis AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| US-12257343-B2 | Excipients to reduce the viscosity of antibody formulations and formulation compositions | AMGEN INC. (US) | 2025-03-25 | — | — | US | disclosed |
| CN-119613487-A | Antibody drug conjugates with linkers comprising hydrophilic groups | 诺华股份有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-119613486-A | Antibody drug conjugates with linkers comprising hydrophilic groups | 诺华股份有限公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20250076310-A1 | METHODS TO CHARACTERIZING A FRAGMENT CRYSTALLIZABLE DOMAIN OF A BISPECIFIC ANTIBODY | REGENERON PHARMA (US) | 2025-03-06 | — | — | US | disclosed |
| EP-4489792-A1 | PHENYL MALEIMIDE LINKER AGENTS | Firefly Bio, Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| CN-113853219-B | Antibody drug conjugates with linkers comprising hydrophilic groups | 诺华股份有限公司 | 2025-01-07 | — | — | CN | disclosed |
| EP-4477667-A2 | FORMULATIONS OF HUMAN ANTI-RANKL ANTIBODIES, AND METHODS OF USING THE SAME | Amgen Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| CN-119119176-A | Camptothecin derivatives | 伊缪诺金公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-119080883-A | Antibacterial peptide and application thereof | 合肥科生景肽生物科技有限公司 | 2024-12-06 | — | — | CN | disclosed |
| US-20240391954-A1 | MC4R AGONIST PEPTIDES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-11-28 | — | — | US | disclosed |
| US-20240390451-A1 | MODIFIED TRIPEPTIDES FOR USE IN THE TREATMENT OF A NON-ENVELOPED VIRUS INFECTION | PHARMA HOLDINGS AS (NO) | 2024-11-28 | — | — | US | disclosed |
| CN-118987200-A | Formulations of human anti-RANKL antibodies and methods of use thereof | 美国安进公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2024238872-A2 | ISOINDOLINONE-GLUTARIMIDE ANTIBODY CONJUGATES, AND USES THEREOF | FIREFLY BIO, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| US-20240366627-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-11-07 | — | — | US | disclosed |
| US-20240315296-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | CJ CHEILJEDANG CORPORATION (KR) | 2024-09-26 | — | — | US | disclosed |
| EP-4190355-B1 | FORMULATIONS OF HUMAN ANTI-RANKL ANTIBODIES, AND METHODS OF USING THE SAME | AMGEN INC (US) | 2024-09-25 | — | — | EP | disclosed |
| CN-113766954-B | Camptothecin derivatives | 伊缪诺金公司 | 2024-09-24 | — | — | CN | disclosed |
| US-20240307561-A1 | RADIOLABELED PARP INHIBITOR CONJUGATES FOR CANCER TREATMENT | DUKE UNIVERSITY (US) | 2024-09-19 | — | — | US | disclosed |
| WO-2024189481-A1 | PANRAS INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2024-09-19 | — | — | WO | disclosed |
| US-20240299572-A1 | NITROGEN-CONTAINING COMPOUND, CONJUGATE CONTAINING SAID COMPOUND, AND APPLICATION THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2024-09-12 | — | — | US | disclosed |
| EP-4422658-A1 | MODIFIED TRIPEPTIDES FOR USE IN THE TREATMENT OF A NON-ENVELOPED VIRUS INFECTION | Pharma Holdings AS (NO) | 2024-09-04 | — | — | EP | disclosed |
| US-20240279292-A1 | ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICES | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 2024-08-22 | — | — | US | disclosed |
| US-20240269304-A1 | BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | LES LABORATOIRES SERVIER (FR) | 2024-08-15 | — | — | US | disclosed |
| CN-110621342-B | Formulations of human anti-RANKL antibodies and methods of use thereof | 美国安进公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-118302183-A | Modified tripeptides for use in the treatment of non-enveloped viral infections | 制药控股有限公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2024132726-A1 | SERUM PEPTIDE PATTERNS FOR DIAGNOSTICS OF ACUTE ISCHEMIC STROKE IN HUMANS AND DIFFERENTIAL DIAGNOSIS OF ACUTE ISCHEMIC STROKE FROM INTRACRANIAL HEMORRHAGIC STROKE | UNIWERSYTET GDANSKI (PL) | 2024-06-27 | — | — | WO | disclosed |
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2024-06-20 | — | — | US | disclosed |
| WO-2024123698-A1 | METHODS TO CHARACTERIZING A FRAGMENT CRYSTALLIZABLE DOMAIN OF A BISPECIFIC ANTIBODY | REGENERON PHARMACEUTICALS, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| US-11987607-B2 | Antimicrobial peptides with alpha-core helices | The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (US) | 2024-05-21 | — | — | US | disclosed |
| EP-4153242-B1 | PARA-AMINO-BENZYL LINKERS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN CONJUGATES | SERVIER LAB (FR) | 2024-05-15 | — | — | EP | disclosed |
| US-20240148819-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SINUSITIS, PNEUMONIA OR OTITIS | PHARMA HOLDINGS AS (NO) | 2024-05-09 | — | — | US | disclosed |
| EP-4364754-A2 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-4364582-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | CJ Cheiljedang Corporation (KR) | 2024-05-08 | — | — | EP | disclosed |
| WO-2024086744-A2 | COMPOSITIONS AND USES THEREOF | SOLVE THERAPEUTICS, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-11963964-B2 | Small molecules for mouse satellite cell proliferation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-04-23 | — | — | US | disclosed |
| CN-110678757-B | Method for diagnosing or monitoring renal function or diagnosing renal dysfunction | 斯弗因高泰克有限公司 | 2024-04-05 | — | — | CN | disclosed |
| EP-4342884-A1 | NITROGEN-CONTAINING COMPOUND, CONJUGATE CONTAINING SAID COMPOUND, AND APPLICATION THEREOF | Shanghai de Novo Pharmatech Co., Ltd. (CN) | 2024-03-27 | — | — | EP | disclosed |
| CN-117757876-A | Double-enzyme catalysis preparation method of 2' -deoxy-2-fluoroadenosine | 上海合润远生物技术有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-20240084068-A1 | POLYMER COMPOUND COMPRISING PENDENT PEPTIDES, METHOD FOR PREPARING SAME AND USES THEREOF | GENEPEP (FR) | 2024-03-14 | — | — | US | disclosed |
| US-20240067640-A1 | PHENYL MALEIMIDE LINKER AGENTS | FIREFLY BIO, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240058450-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2024-02-22 | — | — | US | disclosed |
| US-20240042051-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | LES LABORATOIRES SERVIER (FR) | 2024-02-08 | — | — | US | disclosed |
| EP-4313103-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SINUSITIS, PNEUMONIA OR OTITIS | Pharma Holdings AS (NO) | 2024-02-07 | — | — | EP | disclosed |
| EP-4316524-A2 | CAMPTOTHECIN DERIVATIVES | ImmunoGen, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2024020164-A2 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| EP-4308145-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF AN ENVELOPED VIRUS INFECTION | Pharma Holdings AS (NO) | 2024-01-24 | — | — | EP | disclosed |
| WO-2024015830-A1 | EPCAM IMMUNOCONJUGATES AND USES THEREOF | CYTOMX THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-11873343-B2 | Pharmaceutical formulations comprising anti-RANKL antibodies and an aromatic amino acid comprising a phenyl or an indole | AMGEN INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20240002438-A1 | MELANOCORTIN LIGANDS AND METHODS OF USE THEREOF | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES | 2024-01-04 | — | — | US | disclosed |
| EP-3615066-B1 | FORMULATIONS OF HUMAN ANTI-RANKL ANTIBODIES, AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-12-27 | — | — | EP | disclosed |
| EP-4288062-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | Epalex Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| WO-2023223097-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225320-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225336-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225359-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| US-11807899-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited | 2023-11-07 | — | — | US | disclosed |
| CN-116997349-A | Compounds for use in the treatment of enveloped virus infections | 制药控股有限公司 | 2023-11-03 | — | — | CN | disclosed |
| US-20230312651-A1 | Cyclic Peptide, Peptide Complex, and Drug Composition Containing Said Cyclic Peptide and/or Said Peptide Complex | THE UNIVERSITY OF TOKYO (JP) | 2023-10-05 | — | — | US | disclosed |
| EP-4251209-A1 | BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | Novartis AG (CH) | 2023-10-04 | — | — | EP | disclosed |
| EP-4251208-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2023-10-04 | — | — | EP | disclosed |
| US-11771657-B2 | Methods of delivering a neuroprotective polypeptide to the central nervous system | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230285590-A1 | POLYMER-CARGO-COMPLEXES COMPRISING CROSS-LINKED COPOLYMERS AND CARGO MOLECULES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2023-09-14 | — | — | US | disclosed |
| WO-2023173121-A1 | PHENYL MALEIMIDE LINKER AGENTS | FIREFLY BIO, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20230277567-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2023-09-07 | — | — | US | disclosed |
| US-11730817-B2 | Pro-cyclic dinucleotides and pro-cyclic dinucleotide conjugates for cytokine induction | INVIVOGEN (FR) | 2023-08-22 | — | — | US | disclosed |
| US-20230227516-A1 | ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICES | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER | 2023-07-20 | — | — | US | disclosed |
| US-20230218778-A1 | PARA-AMINO-BENZYL LINKERS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN CONJUGATES | LES LABORATOIRES SERVIER (FR) | 2023-07-13 | — | — | US | disclosed |
| EP-4208174-A2 | NUCLEIC ACID-DERIVATIZED THERAPEUTICS | The University of Chicago (US) | 2023-07-12 | — | — | EP | disclosed |
| WO-2023112872-A1 | NUCLEIC ACID TRANSPORT CARRIER AND NUCLEIC ACID TRANSPORT COMPLEX | 国立大学法人長崎大学 | 2023-06-22 | — | — | WO | disclosed |
| EP-4190355-A1 | FORMULATIONS OF HUMAN ANTI-RANKL ANTIBODIES, AND METHODS OF USING THE SAME | Amgen Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| CN-116178487-A | Method for preparing rapeseed meal oligopeptide by combining superfine grinding and one-step enzymolysis | 农业农村部规划设计研究院 | 2023-05-30 | — | — | CN | disclosed |
| EP-4180446-A1 | CYCLIC PEPTIDE, PEPTIDE COMPLEX, AND DRUG COMPOSITION CONTAINING SAID CYCLIC PEPTIDE AND/OR SAID PEPTIDE COMPLEX | The University of Tokyo (JP) | 2023-05-17 | — | — | EP | disclosed |
| US-20230144728-A1 | MICRO ALGAE CULTURING DEVICE | POON WING HEI DENNIS (HK) | 2023-05-11 | — | — | US | disclosed |
| WO-2023072485-A1 | MODIFIED TRIPEPTIDES FOR USE IN THE TREATMENT OF A NON-ENVELOPED VIRUS INFECTION | PHARMA HOLDINGS AS (NO) | 2023-05-04 | — | — | WO | disclosed |
| US-20230135723-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-05-04 | — | — | US | disclosed |
| EP-4168051-A1 | POLYMER-CARGO-COMPLEXES COMPRISING CROSS-LINKED COPOLYMERS AND CARGO MOLECULES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2023-04-26 | — | — | EP | disclosed |
| US-20230120736-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-11628178-B2 | Fospropofol methods and compositions | EPALEX CORPORATION (US) | 2023-04-18 | — | — | US | disclosed |
| US-20230114718-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-04-13 | — | — | US | disclosed |
| US-20230116913-A2 | PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION | INVIVOGEN (FR) | 2023-04-13 | — | — | US | disclosed |
| US-20230094471-A1 | CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES | IMMUNOGEN, INC. (US) | 2023-03-30 | — | — | US | disclosed |
| US-20230091510-A1 | ANTIBODY DRUG CONJUGATES HAVING LINKERS COMPRISING HYDROPHILIC GROUPS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-03-23 | — | — | US | disclosed |
| US-20230092679-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-03-23 | — | — | US | disclosed |
| US-20230077680-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-03-16 | — | — | US | disclosed |
| US-20230081720-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-03-16 | — | — | US | disclosed |
| US-20230084521-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2023-03-16 | — | — | US | disclosed |
| WO-2023278592-A1 | RADIOLABELED PARP INHIBITOR CONJUGATES FOR CANCER TREATMENT | DUKE UNIVERSITY (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2023277549-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | 씨제이제일제당 (주) | 2023-01-05 | — | — | WO | disclosed |
| EP-4104865-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| CN-114634554-B | Anti-wrinkle cyclic hexapeptide compound and preparation method thereof | 浙江湃肽生物股份有限公司 | 2022-12-06 | — | — | CN | disclosed |
| WO-2022242724-A1 | NITROGEN-CONTAINING COMPOUND, CONJUGATE CONTAINING SAID COMPOUND, AND APPLICATION THEREOF | 上海迪诺医药科技有限公司 | 2022-11-24 | — | — | WO | disclosed |
| US-20220362396-A1 | AMINO-PYRAZINECARBOXAMIDE COMPOUNDS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2022-11-17 | — | — | US | disclosed |
| US-20220339287-A9 | PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION | INVIVOGEN (FR) | 2022-10-27 | — | — | US | disclosed |
| US-20220323596-A1 | ANTIBODY CONJUGATES OF TOLL-LIKE RECEPTOR AGONISTS | SILVERBACK THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2022200224-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SINUSITIS, PNEUMONIA OR OTITIS | PHARMA HOLDINGS AS (NO) | 2022-09-29 | — | — | WO | disclosed |
| US-11453849-B1 | Micro algae culturing device | POON WING HEI DENNIS (HK) | 2022-09-27 | — | — | US | disclosed |
| WO-2022195097-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF AN ENVELOPED VIRUS INFECTION | PHARMA HOLDINGS AS (NO) | 2022-09-22 | — | — | WO | disclosed |
| US-20220298135-A1 | 5-HETEROARYL-PYRIDIN-2-AMINE COMPOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2022-09-22 | — | — | US | disclosed |
| CN-115044652-A | Nucleic acid detection kit based on CRISPR/Cas12a system and up-conversion luminescent particle immunochromatography and application | 中国人民解放军军事科学院军事医学研究院 | 2022-09-13 | — | — | CN | disclosed |
| CN-115047120-A | Dansyl chloride derivatization method for analyzing and detecting dipeptide substances in white spirit Daqu | 贵州茅台酒股份有限公司 | 2022-09-13 | — | — | CN | disclosed |
| US-11426400-B2 | Methods of increasing satellite cell proliferation with vorinostat or bosutinib | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220265563-A1 | METHODS OF DELIVERING A NEUROPROTECTIVE POLYPEPTIDE TO THE CENTRAL NERVOUS SYSTEM | PEPTRON, INC. (KR) | 2022-08-25 | — | — | US | disclosed |
| US-20220265686-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2022-08-25 | — | — | US | disclosed |
| WO-2022173981-A1 | INTRAVENOUS ADMINISTRATION OF ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES | PEPTILOGICS, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| WO-2022169520-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | EPALEX CORPORATION (US) | 2022-08-11 | — | — | WO | disclosed |
| CN-114667134-A | Formulations of benzazepine conjugates and uses thereof | 希沃尔拜克治疗公司 | 2022-06-24 | — | — | CN | disclosed |
| WO-2022128940-A1 | POLYMER COMPOUND COMPRISING PENDENT PEPTIDES, METHOD FOR PREPARING SAME AND USES THEREOF | GENEPEP (FR) | 2022-06-23 | — | — | WO | disclosed |
| CN-114634554-A | Anti-wrinkle cyclic hexapeptide compound and preparation method thereof | 浙江湃肽生物股份有限公司 | 2022-06-17 | — | — | CN | disclosed |
| EP-4010328-A1 | 5-HETEROARYL-PYRIDIN-2-AMINE CONFOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | Domain Therapeutics (FR) | 2022-06-15 | — | — | EP | disclosed |
| EP-4011932-A1 | POLYMER COMPOUND WITH PENDANT PEPTIDES, METHOD FOR PREPARING SAME AND USES THEREOF | Genepep (FR) | 2022-06-15 | — | — | EP | disclosed |
| WO-2022115451-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| US-20220169660-A1 | CYCLIC AMINO-PYRAZINECARBOXAMIDE COMPOUNDS AND USES THEREOF | SILVERBACK THERAPEUTICS INC (US) | 2022-06-02 | — | — | US | disclosed |
| WO-2022115477-A1 | BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| CN-114478789-A | anti-PD-L1 and OX40 bispecific antibodies and uses thereof | 安徽安科生物工程（集团）股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| US-20220145378-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-05-12 | — | — | US | disclosed |
| US-20220143181-A1 | FORMULATIONS OF HUMAN ANTI-RANKL ANTIBODIES, AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2022-05-12 | — | — | US | disclosed |
| US-20220133839-A1 | PEPTIDE ANALOGUES WITH BRANCHED AMINO ACID PROBE(S) | TXP PHARMA GMBH (CH) | 2022-05-05 | — | — | US | disclosed |
| US-20220133711-A1 | CAMPTOTHECIN DERIVATIVES | IMMUNOGEN, INC. | 2022-05-05 | — | — | US | disclosed |
| EP-3468996-B1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2022-05-04 | — | — | EP | disclosed |
| US-20220118004-A1 | TUNABLE IMMUNE RESPONSIVE BIODEGRADABLE ARGININE-BASED POLY(ESTER AMIDE)S AND METHODS OF MAKING AND USING SAME | UNIV CORNELL (US) | 2022-04-21 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
| US-20220105196-A1 | NECTIN-4 ANTIBODY CONJUGATES AND USES THEREOF | ARARIS BIOTECH AG (CH) | 2022-04-07 | — | — | US | disclosed |
| US-20220105050-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2022-04-07 | — | — | US | disclosed |
| CN-114269730-A | 5-heteroaryl-pyridin-2-amine compounds as neuropeptide FF receptor antagonists | 多曼治疗学公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3972650-A2 | ANTIBODY DRUG CONJUGATES HAVING LINKERS COMPRISING HYDROPHILIC GROUPS | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| EP-3972651-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| EP-3972649-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| US-11273130-B2 | Methods of delivering a neuroprotective polypeptide to the central nervous system | The United States, as represented by the Secretary Department of Health and Human Services (US) | 2022-03-15 | — | — | US | disclosed |
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-02-24 | — | — | US | disclosed |
| US-11229639-B2 | Camptothecin derivatives | IMMUNOGEN, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| EP-3478121-A1 | METHOD FOR SAMPLING GINGIVAL METABOLITES | The Procter and Gamble Company (US) | 2019-05-08 | — | — | EP | disclosed |
| US-10267797-B2 | Detection of oral microbial virulence factors | THE PROCTER & GAMBLE COMPANY (US) | 2019-04-23 | — | — | US | disclosed |
| CN-109414109-A | Method for sampling gums metabolin | 宝洁公司 | 2019-03-01 | — | — | CN | disclosed |
| US-10156566-B2 | Detoxification of microbial virulence factors in oral cavity | THE PROCTER & GAMBLE COMPANY (US) | 2018-12-18 | — | — | US | disclosed |
| US-9970934-B2 | Detection of oral microbial virulence factors | THE PROCTER & GAMBLE COMPANY (US) | 2018-05-15 | — | — | US | disclosed |
| US-9964472-B2 | Methods for sampling gingival metabolites | THE PROCTER & GAMBLE COMPANY (US) | 2018-05-08 | — | — | US | disclosed |
| EP-3292215-A1 | DETOXIFICATION OF MICROBIAL VIRULENCE FACTORS IN ORAL CAVITY | The Procter and Gamble Company (US) | 2018-03-14 | — | — | EP | disclosed |
| US-20180003598-A1 | METHODS FOR SAMPLING GINGIVAL METABOLITES | THE PROCTER & GAMBLE COMPANY | 2018-01-04 | — | — | US | disclosed |
| WO-2018005335-A1 | METHOD FOR SAMPLING GINGIVAL METABOLITES | THE PROCTER & GAMBLE COMPANY (US) | 2018-01-04 | — | — | WO | disclosed |
| US-20170119643-A1 | DETOXIFICATION OF MICROBIAL VIRULENCE FACTORS IN ORAL CAVITY | THE PROCTER & GAMBLE COMPANY | 2017-05-04 | — | — | US | disclosed |
| WO-2016179561-A1 | DETOXIFICATION OF MICROBIAL VIRULENCE FACTORS IN ORAL CAVITY | THE PROCTER & GAMBLE COMPANY (US) | 2016-11-10 | — | — | WO | disclosed |
| US-20160327557-A1 | DETECTION OF ORAL MICROBIAL VIRULENCE FACTORS | THE PROCTER & GAMBLE COMPANY | 2016-11-10 | — | — | US | disclosed |
| EP-3042718-A1 | DEVICE FOR SOLUBILIZING, SEPARATING, REMOVING AND REACTING CARBOXYLIC ACIDS IN OILS, FATS, AQUEOUS OR ORGANIC SOLUTIONS BY MEANS OF MICRO- OR NANOEMULSIFICATION | Dietz, Ulrich (DE) | 2016-07-13 | — | — | EP | disclosed |
| US-20160122686-A1 | DEVICE AND METHOD FOR SOLUBILIZING, SEPARATING, REMOVING AND REACTING CARBOXYLIC ACIDS IN OILS, FATS, AQUEOUS OR ORGANIC SOLUTIONS BY MEANS OF MICRO-OR NANOEMULSIFICATION | DIETZ ULRICH (DE) | 2016-05-05 | — | — | US | disclosed |
| CN-103038195-B | Device and method for solubilizing, separating, removing and reacting carboxylic acids in oils, fats, aqueous or organic solutions by micro-or nanoemulsification | ULRICH DIETZ (DE) | 2016-04-13 | — | — | CN | disclosed |
| EP-2585420-B1 | METHOD FOR SOLUBILIZING, SEPARATING, REMOVING AND REACTING CARBOXYLIC ACIDS IN OILS, FATS, AQUEOUS OR ORGANIC SOLUTIONS BY MEANS OF MICRO- OR NANOEMULSIFICATION | DIETZ ULRICH (DE) | 2016-04-06 | — | — | EP | disclosed |
| US-9127233-B2 | Device and method for solubilizing, separating, removing and reacting carboxylic acids in oils, fats, aqueous or organic solutions by means of micro-or nanoemulsification | Dietz, Ulrich (DE) | 2015-09-08 | — | — | US | disclosed |
| US-20140343865-A1 | Biomarkers for Kidney Cancer and Methods Using the Same | METABOLON, INC. | 2014-11-20 | — | — | US | disclosed |
| EP-2585420-A2 | DEVICE AND METHOD FOR SOLUBILIZING, SEPARATING, REMOVING AND REACTING CARBOXYLIC ACIDS IN OILS, FATS, AQUEOUS OR ORGANIC SOLUTIONS BY MEANS OF MICRO- OR NANOEMULSIFICATION | Dietz, Ulrich (DE) | 2013-05-01 | — | — | EP | disclosed |
| US-20130090488-A1 | DEVICE AND METHOD FOR SOLUBILIZING, SEPARATING, REMOVING AND REACTING CARBOXYLIC ACIDS IN OILS, FATS, AQUEOUS OR ORGANIC SOLUTIONS BY MEANS OF MICRO-OR NANOEMULSIFICATION | DIETZ ULRICH (DE) | 2013-04-11 | — | — | US | disclosed |
| CN-103038195-A | Device and method for solubilizing, separating, removing and reacting carboxylic acids in oils, fats, aqueous or organic solutions by micro-or nanoemulsification | DIETZ ULRICH | 2013-04-10 | — | — | CN | disclosed |
| WO-2011160857-A2 | DEVICE AND METHOD FOR SOLUBILIZING, SEPARATING, REMOVING AND REACTING CARBOXYLIC ACIDS IN OILS, FATS, AQUEOUS OR ORGANIC SOLUTIONS BY MEANS OF MICRO- OR NANOEMULSIFICATION | DIETZ ULRICH (DE) | 2011-12-29 | — | — | WO | disclosed |
| EP-2399885-A1 | Device and method for solubilizing, separating, removing and reacting carboxylic acids in aqueous or organic solutions by means of micro- or nanoemulsification | Dietz, Ulrich (DE) | 2011-12-28 | — | — | EP | disclosed |
| EP-2172545-A1 | Preparation of purified peptide deformylase | DSM IP Assets B.V. (NL) | 2010-04-07 | — | — | EP | disclosed |
| US-5869606-A | REACTING N-PROTECTED AMINO ACID OR PEPTIDE ESTER WITH ETHANOLAMINE IN THE PRESENCE OF 60% AQUEOUS DIMETHYLFORMAMIDE, ESTERIFICATION WITH FATTY ACID | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1999-02-09 | — | — | US | disclosed |
| US-5869606-A | REACTING N-PROTECTED AMINO ACID OR PEPTIDE ESTER WITH ETHANOLAMINE IN THE PRESENCE OF 60% AQUEOUS DIMETHYLFORMAMIDE, ESTERIFICATION WITH FATTY ACID | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1999-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146045-A1 | COMPOSITIONS AND USES THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2, NR3C2 | NPY4R 1275/4885NPY1R 1003/4885NPY2R 471/4885 |
| US-20220265563-A1 | METHODS OF DELIVERING A NEUROPROTECTIVE POLYPEPTIDE TO THE CENTRAL NERVOUS SYSTEM | GLP1R, IAPP, BDNF | NPY4R 9/4885NPY1R 10/4885NPY2R 13/4885 |
| US-20230092679-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MCL1, BCL9, BAK1 | NPY4R 4874/4885NPY1R 4752/4885NPY2R 4871/4885 |
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | NPY4R 2363/4885NPY1R 2412/4885NPY2R 2633/4885 |
| US-20230114718-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | NPY4R 2363/4885NPY1R 2412/4885NPY2R 2633/4885 |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | NPY4R 2363/4885NPY1R 2412/4885NPY2R 2633/4885 |
| US-20230135723-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD99, SLC3A2, CD63 | NPY4R 4746/4885NPY1R 4701/4885NPY2R 4321/4885 |
| US-20260000777-A1 | NECTIN-4 ANTIBODY CONJUGATES AND USES THEREOF | NECTIN4, IGSF11, VSIG8 | NPY4R 1966/4885NPY1R 2683/4885NPY2R 3451/4885 |
| US-11873343-B2 | Pharmaceutical formulations comprising anti-RANKL antibodies and an aromatic amino acid comprising a phenyl or an indole | TNF, TRAF6, TNFRSF9 | NPY4R 458/4885NPY1R 111/4885NPY2R 301/4885 |
| US-20230312651-A1 | Cyclic Peptide, Peptide Complex, and Drug Composition Containing Said Cyclic Peptide and/or Said Peptide Complex | NPPA, NGLY1, NPR1 | NPY4R 22/4885NPY1R 15/4885NPY2R 40/4885 |
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | MKI67, MYLK2, MYH2 | NPY4R 4284/4885NPY1R 4277/4885NPY2R 4339/4885 |
| US-11628178-B2 | Fospropofol methods and compositions | FOS, FOSB, PFAS | NPY4R 879/4885NPY1R 2530/4885NPY2R 1464/4885 |
| US-20240148819-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SINUSITIS, PNEUMONIA OR OTITIS | MRGPRX2, EPX, CCL11 | NPY4R 507/4885NPY1R 159/4885NPY2R 215/4885 |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | EPHA2, EPHA1, EPHB1 | NPY4R 518/4885NPY1R 143/4885NPY2R 283/4885 |
| US-20240391954-A1 | MC4R AGONIST PEPTIDES | MC4R, MC3R, MC5R | NPY4R 6/4885NPY1R 9/4885NPY2R 17/4885 |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | NR3C1, NR3C2, MC2R | NPY4R 460/4885NPY1R 451/4885NPY2R 502/4885 |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | BID, BCL2, MCL1 | NPY4R 4455/4885NPY1R 4093/4885NPY2R 4219/4885 |
| US-20240084068-A1 | POLYMER COMPOUND COMPRISING PENDENT PEPTIDES, METHOD FOR PREPARING SAME AND USES THEREOF | VIP, PSAP, NGLY1 | NPY4R 935/4885NPY1R 914/4885NPY2R 928/4885 |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | MET, BCL3, BCL9 | NPY4R 3683/4885NPY1R 3973/4885NPY2R 4161/4885 |
| US-11730817-B2 | Pro-cyclic dinucleotides and pro-cyclic dinucleotide conjugates for cytokine induction | STING1, CGAS, TLR9 | NPY4R 2363/4885NPY1R 2233/4885NPY2R 2593/4885 |
| US-20250312361-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | FOS, FOSB, PFAS | NPY4R 879/4885NPY1R 2530/4885NPY2R 1464/4885 |
| US-20250367115-A1 | Excipients To Reduce the Viscosity of Antibody Formulations and Formulation Compositions | ARGLU1, ARG1, FCGRT | NPY4R 1403/4885NPY1R 1084/4885NPY2R 1670/4885 |
| US-12590131-B2 | Antimicrobial peptides with alpha-core helices | VIP, HAMP, HM13 | NPY4R 781/4885NPY1R 643/4885NPY2R 998/4885 |
| US-20240299572-A1 | NITROGEN-CONTAINING COMPOUND, CONJUGATE CONTAINING SAID COMPOUND, AND APPLICATION THEREOF | TLR8, TLR9, TLR7 | NPY4R 4216/4885NPY1R 3696/4885NPY2R 3699/4885 |
| US-20250263491-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | NPY4R 2363/4885NPY1R 2412/4885NPY2R 2633/4885 |
| US-20230285590-A1 | POLYMER-CARGO-COMPLEXES COMPRISING CROSS-LINKED COPOLYMERS AND CARGO MOLECULES | KPNA6, EEA1, RAB5IF | NPY4R 3682/4885NPY1R 3711/4885NPY2R 4079/4885 |
| US-20220118004-A1 | TUNABLE IMMUNE RESPONSIVE BIODEGRADABLE ARGININE-BASED POLY(ESTER AMIDE)S AND METHODS OF MAKING AND USING SAME | ARG1, LRBA, ARG2 | NPY4R 1005/4885NPY1R 1279/4885NPY2R 1622/4885 |
| US-20230120736-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD99, SLC3A2, CD63 | NPY4R 4746/4885NPY1R 4701/4885NPY2R 4321/4885 |
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | FCGR2A, FCGR3B, BCL3 | NPY4R 3679/4885NPY1R 1968/4885NPY2R 2528/4885 |
| US-20240307561-A1 | RADIOLABELED PARP INHIBITOR CONJUGATES FOR CANCER TREATMENT | PARP1, PARP2, PARP3 | NPY4R 3932/4885NPY1R 3514/4885NPY2R 4192/4885 |
| US-20230094471-A1 | CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES | GABBR2, GABRB1, GABRB2 | NPY4R 1324/4885NPY1R 625/4885NPY2R 784/4885 |
| US-20220133711-A1 | CAMPTOTHECIN DERIVATIVES | TOP2A, TOP2B, PCNA | NPY4R 4883/4885NPY1R 4885/4885NPY2R 4882/4885 |
| US-20230081720-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MCL1, CD74, CD99 | NPY4R 4873/4885NPY1R 4815/4885NPY2R 4852/4885 |
| US-20250326853-A1 | FORMULATIONS OF HUMAN ANTI-RANKL ANTIBODIES, AND METHODS OF USING THE SAME | TNF, TNFSF11, TNFRSF9 | NPY4R 1631/4885NPY1R 747/4885NPY2R 1351/4885 |
| US-11273130-B2 | Methods of delivering a neuroprotective polypeptide to the central nervous system | GLP1R, IAPP, BDNF | NPY4R 9/4885NPY1R 10/4885NPY2R 13/4885 |
| US-20240366627-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | MKI67, MYLK2, MYH2 | NPY4R 4284/4885NPY1R 4277/4885NPY2R 4339/4885 |
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | NPY4R 4433/4885NPY1R 3079/4885NPY2R 3236/4885 |
| US-20220323596-A1 | ANTIBODY CONJUGATES OF TOLL-LIKE RECEPTOR AGONISTS | TLR7, TLR9, TLR3 | NPY4R 941/4885NPY1R 767/4885NPY2R 1125/4885 |
| US-20240042051-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MCL1, CD58, LENG8 | NPY4R 4885/4885NPY1R 4864/4885NPY2R 4882/4885 |
| US-20240390451-A1 | MODIFIED TRIPEPTIDES FOR USE IN THE TREATMENT OF A NON-ENVELOPED VIRUS INFECTION | LNPEP, ANPEP, ENPEP | NPY4R 1686/4885NPY1R 1688/4885NPY2R 2749/4885 |
| US-20240269304-A1 | BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | BCL3, BCL9, BCL2L10 | NPY4R 4213/4885NPY1R 4230/4885NPY2R 4396/4885 |
| US-20220105196-A1 | NECTIN-4 ANTIBODY CONJUGATES AND USES THEREOF | NECTIN4, SIGLEC7, CD2 | NPY4R 1795/4885NPY1R 3878/4885NPY2R 3846/4885 |
| US-20230218778-A1 | PARA-AMINO-BENZYL LINKERS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN CONJUGATES | DNPEP, PEPD, PREP | NPY4R 2900/4885NPY1R 3597/4885NPY2R 4045/4885 |
| US-11963964-B2 | Small molecules for mouse satellite cell proliferation | MKI67, MYLK2, MYH2 | NPY4R 4284/4885NPY1R 4277/4885NPY2R 4339/4885 |
| US-20230077680-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | NPY4R 2363/4885NPY1R 2412/4885NPY2R 2633/4885 |
| US-20220362396-A1 | AMINO-PYRAZINECARBOXAMIDE COMPOUNDS, CONJUGATES, AND USES THEREOF | TGFBR2, SMAD2, ACVR2A | NPY4R 579/4885NPY1R 335/4885NPY2R 132/4885 |
| US-20230091510-A1 | ANTIBODY DRUG CONJUGATES HAVING LINKERS COMPRISING HYDROPHILIC GROUPS | CD44, IGSF11, ABCC1 | NPY4R 3628/4885NPY1R 4424/4885NPY2R 4490/4885 |
| US-12257343-B2 | Excipients to reduce the viscosity of antibody formulations and formulation compositions | ARGLU1, ARG1, FCGRT | NPY4R 1403/4885NPY1R 1084/4885NPY2R 1670/4885 |
| US-11987607-B2 | Antimicrobial peptides with alpha-core helices | VIP, NGLY1, SPPL2B | NPY4R 2497/4885NPY1R 2087/4885NPY2R 2739/4885 |
| US-20230277567-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | FOS, FOSB, PFAS | NPY4R 879/4885NPY1R 2530/4885NPY2R 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.